Mitchell E. Gross, MD, PhD
Associate Professor of Clinical Medicine | Research Director
310 272 7640 | mitchell.gross@ellison.usc.edu
Dr. Gross is an Associate Professor of Clinical Medicine at the Keck School of Medicine of USC and the Research Director of the Lawrence J. Ellison Institute of USC. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) to the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase I and II clinical trials. Dr. Gross has earned degrees from the University of California, San Diego (BA), Baylor College of Medicine in Houston (MD), and the University of California, Los Angeles (PhD in Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

Research Focus

Cancer Treatment
Personalized Medicine
Physical Sciences in Oncology
Molecular Biology of Cancer

Joanna Chen, MS
Chun-Peng Liao, PhD
Ailin Zhang

Education

BA

1990 Biochemistry/Cell Biology – University of California, San Diego, CA  

Md

1994 Medicine – Baylor College of Medicine, Houston, TX  

PhD

2003 University of California – Los Angeles, CA  

Residency

1994-1997 Resident in Internal Medicine – UCLA School of Medicine, Los Angeles, CA  

Fellowship

1997-2002 Fellow in Hematology/Oncology – UCLA School of Medicine, Los Angeles, CA  

Awards

Specialty Training Research Fellowship, 1997 to 2002
AACR-AFLAC Scholar in Training Award, 2001 
Rhone Phoulenc Rorer Travel Award, 1999 
Amgen Fellowship Research Award, 1999 
Alpha Omega Alpha, 1994 
Hewlett Packard Award for Excellence in Internal Medicine, 1994 
UCSD/Revelle College Academic Leadership Award, 1990 
Phi Beta Kappa, 1989 
Donna and Jesse Garber Award 

Selected Publications

Gaur S, Gross ME, Liao CP, Qian B, Shih JC. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Prostate. 2019 May;79(6):667-677. View in: PubMed
Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 Mar 19. View in: PubMed
Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, Perakis S, Gormley M, Patel J, Li W, Geigl JB, Smirnov D, Heitzer E, Gross M, Speicher MR. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer. 2018 Sep 1;143(5):1236-1248. View in: PubMed
Liao CP, Lin TP, Li PC, Geary LA, Chen K, Vaikari VP, Wu JB, Lin CH, Gross ME, Shih JC. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene. 2018 Sep;37(38):5175-5190. View in: PubMed
Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer. 2018 Apr 3;18(1):368. View in: PubMed
Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. View in: PubMed
Tennill TA, Gross ME, Frieboes HB. Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS One. 2017;12(5):e0178362. View in: PubMed
Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross ME. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocr Relat Cancer. 2017 Apr;24(4):157-170. View in: PubMed  
Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME, Hicks J, Kuhn P. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9(8):e101777. View in: PubMed
Wang L, Li Y, Lin A, Choe Y, Gross ME, Kim ES. A Self-Focusing Acoustic Transducer That Exploits Cytoskeletal Differences for Selective Cytolysis of Cancer Cell. Journal of microelectromechanical systems : a joint IEEE and ASME publication on microstructures, microactuators, microsensors, and microsystems. 2014; 22(3):542. View here
Mitchell E. Gross, MD, PhD
Associate Professor of Clinical Medicine | Research Director
310 272 7640 | mitchell.gross@ellison.usc.edu
Dr. Gross is an Associate Professor of Clinical Medicine at the Keck School of Medicine of USC and the Research Director of the Lawrence J. Ellison Institute of USC. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) to the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase I and II clinical trials. Dr. Gross has earned degrees from the University of California, San Diego (BA), Baylor College of Medicine in Houston (MD), and the University of California, Los Angeles (PhD in Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

Research Focus

Cancer Treatment
Personalized Medicine
Physical Sciences in Oncology
Molecular Biology of Cancer

Joanna Chen, MS
Chun-Peng Liao, PhD
Ailin Zhang

Education

BA

1990 Biochemistry/Cell Biology – University of California, San Diego, CA  

Md

1994 Medicine – Baylor College of Medicine, Houston, TX  

PhD

2003 University of California – Los Angeles, CA  

Residency

1994-1997 Resident in Internal Medicine – UCLA School of Medicine, Los Angeles, CA  

Fellowship

1997-2002 Fellow in Hematology/Oncology – UCLA School of Medicine, Los Angeles, CA  

Awards

Specialty Training Research Fellowship, 1997 to 2002
AACR-AFLAC Scholar in Training Award, 2001 
Rhone Phoulenc Rorer Travel Award, 1999 
Amgen Fellowship Research Award, 1999 
Alpha Omega Alpha, 1994 
Hewlett Packard Award for Excellence in Internal Medicine, 1994 
UCSD/Revelle College Academic Leadership Award, 1990 
Phi Beta Kappa, 1989 
Donna and Jesse Garber Award 

Selected Publications

Gaur S, Gross ME, Liao CP, Qian B, Shih JC. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells. Prostate. 2019 May;79(6):667-677. View in: PubMed
Dorff TB, Quinn DI, Pinski JK, Goldkorn A, Sadeghi S, Tsao-Wei D, Groshen S, Kuhn P, Gross ME. Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2019 Mar 19. View in: PubMed
Belic J, Graf R, Bauernhofer T, Cherkas Y, Ulz P, Waldispuehl-Geigl J, Perakis S, Gormley M, Patel J, Li W, Geigl JB, Smirnov D, Heitzer E, Gross M, Speicher MR. Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer. 2018 Sep 1;143(5):1236-1248. View in: PubMed
Liao CP, Lin TP, Li PC, Geary LA, Chen K, Vaikari VP, Wu JB, Lin CH, Gross ME, Shih JC. Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate. Oncogene. 2018 Sep;37(38):5175-5190. View in: PubMed
Dawson JK, Dorff TB, Todd Schroeder E, Lane CJ, Gross ME, Dieli-Conwright CM. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial. BMC Cancer. 2018 Apr 3;18(1):368. View in: PubMed
Gross ME, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. View in: PubMed
Tennill TA, Gross ME, Frieboes HB. Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS One. 2017;12(5):e0178362. View in: PubMed
Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross ME. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocr Relat Cancer. 2017 Apr;24(4):157-170. View in: PubMed  
Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross ME, Hicks J, Kuhn P. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9(8):e101777. View in: PubMed
Wang L, Li Y, Lin A, Choe Y, Gross ME, Kim ES. A Self-Focusing Acoustic Transducer That Exploits Cytoskeletal Differences for Selective Cytolysis of Cancer Cell. Journal of microelectromechanical systems : a joint IEEE and ASME publication on microstructures, microactuators, microsensors, and microsystems. 2014; 22(3):542. View here